For the financial period ending June 30 2023, PFIZER INC ($NYSE:PFE) reported a 54.1% decrease in total revenue, amounting to USD 12.7 billion, and a 76.5% drop in net income to USD 2.3 billion when compared to year-on-year results for the same quarter. The figures were released on August 1 2023.
On Tuesday, PFIZER INC (NYSE: PFE) reported its FY2023 Q2 earnings results as of June 30, 2023. The stock opened at $35.9 and closed at $35.6, representing a 1.2% dip from its last closing price of $36.1. This was the company’s first quarter since announcing a major reorganization in April, and investors were eager to see how the new direction would affect the company’s bottom line.
PFIZER INC’s stock responded to the news by declining 1.2%, though analysts say that the company is still on track to reach its goals of generating long-term value for shareholders. Going forward, investors will be monitoring to see if PFIZER INC can capitalize on its growth potential and continue to deliver strong financial performance. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pfizer Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pfizer Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pfizer Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pfizer Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Pfizer Inc Intrinsic Value
At GoodWhale, we have conducted an analysis of PFIZER INC‘s fundamentals to determine its fair value. According to our proprietary Valuation Line, the fair value of PFIZER INC stock is around $45.6. Currently, the stock is being traded at $35.6, which implies it is undervalued by 21.9%. Therefore, we believe that now might be a good time for investors to consider buying PFIZER INC shares. More…
Risk Rating Analysis
Star Chart Analysis
In the pharmaceutical industry, competition is fierce between companies striving to bring innovative new drugs to market. Among the leaders in this industry are Pfizer Inc and its competitors Astellas Pharma Inc, Roche Holding AG, and AstraZeneca PLC. While each company has its own strengths and weaknesses, they all share a commitment to research and development in an effort to stay ahead of the competition.
– Astellas Pharma Inc ($TSE:4503)
Astellas Pharma Inc is a Japanese pharmaceutical company with a market cap of 3.61T as of 2022. The company’s ROE is 6.6%. Astellas Pharma is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company’s products include ethical drugs, over-the-counter drugs, and generic drugs. Astellas Pharma also has a clinical research division that conducts clinical trials of new drugs.
Roche Holding AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. The company was founded in 1896 by Fritz Hoffmann-La Roche. Roche is the world’s largest biotech company, with products in the areas of pharmaceuticals, diagnostics, and consumer health. The company’s mission is to “improve lives by enabling people to do more, feel better, and live longer.”
Roche Holding AG has a market cap of 270.34B as of 2022, a Return on Equity of 47.83%. The company’s strong market position and financial performance are due to its innovative products and services, which address a broad range of medical needs. Roche is committed to research and development, and has a strong pipeline of new products in development. The company’s focus on customer needs and its ability to bring new products to market quickly have resulted in strong financial performance and shareholder value.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a pharmaceutical company with a market cap of 152.81 billion as of 2022. The company has a return on equity of -0.94%. AstraZeneca PLC is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and biologic products for the treatment of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory diseases.
Pfizer Inc. has reported its financial results for the second quarter of 2023, ending June 30th. Total revenue for the quarter decreased by 54.1% to USD 12.7 billion compared to the same quarter of the previous year, while net income dropped by 76.5% to USD 2.3 billion. For investors, this news suggests a challenging outlook for Pfizer Inc. going forward, as evidenced by the sharp declines in revenue and income. Going forward, analysts will be closely monitoring the company’s performance and attempting to determine the best course of action for investors.